AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1592575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6375274 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg/ml
Number of subjects: 275
Study 6375274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicomorphine 10 mg/ml
Number of subjects: 275
Study 6375274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 75 mg/ml
Number of subjects: 275
Study 30664050 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation with methadone maintenance treatment
Number of subjects: 60
Study 30664050 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation with methadone maintenance treatment
Number of subjects: 60
Study 30664050 — intervention group
Group type: COMPARATOR
Intervention: Only methadone maintenance treatment
Number of subjects: 60
Study 29565950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) on the ilioinguinal nerve and genital branch of the genitofemoral nerve
Number of subjects: 70
Study 29565950 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 70
Study 27380105 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 60
Study 27380105 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular and axillary nerve block (SSAX)
Number of subjects: 60
Study 23012688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4408
Study 23012688 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4408
Study 22340283 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 (50 or 250 units/kg single doses; multiple doses of 250 units/kg loading and 50 units/kg maintenance, 500 units/kg loading and 100 units/kg maintenance, or 750 units/kg loading and 250 units/kg maintenance)
Number of subjects: 70
Study 22340283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19877169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG), 8 mg/day for 2 years
Number of subjects: 44
Study 19877169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB) followed by Rosiglitazone (RSG)
Number of subjects: 44
Study 19877169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) for 2 additional years after initial treatment
Number of subjects: 44
Study 17510102 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for problematic alcohol consumption using the Alcohol Use Disorders Identification Test
Number of subjects: 3003
Study 17510102 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral behaviour of physicians
Number of subjects: 3003
Study 15984513 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 0
Study 15984513 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur
Number of subjects: 0
Study 12105140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/d)
Number of subjects: 63
Study 12105140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10420109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3% eye drops twice daily
Number of subjects: 99
Study 10420109 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3% eye drops 4 times daily
Number of subjects: 99
Study 7498114 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who rated negative affect situations as most difficult
Number of subjects: 93
Study 7498114 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who generated coping responses to more situations
Number of subjects: 93
Study 1341875 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril associated with conventional treatment (digitalis and diuretic)
Number of subjects: 20
Study 1341875 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril associated with digitalis or diuretic
Number of subjects: 20
Study 1341875 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (digitalis and diuretic)
Number of subjects: 20
Study 6659641 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (negative inotropic agent)
Number of subjects: 23
Study 6659641 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐L 115 BS (positive inotropic drug)
Number of subjects: 23
Study 6659641 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol during atrial pacing
Number of subjects: 23
Study 6659641 — intervention group
Group type: COMPARATOR
Intervention: Control values under physiological conditions
Number of subjects: 23
Study 30924348 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of previously published criteria for GPA diagnosis
Number of subjects: 132
Study 30924348 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of antineutrophil cytoplasm autoantibody testing and the European Medicines Agency algorithm
Number of subjects: 132
Study 30924348 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized disease
Number of subjects: 132
Study 30924348 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver correlation among pathologists
Number of subjects: 132
Study 29378016 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (150 mg)
Number of subjects: 24
Study 29378016 — intervention group
Group type: COMPARATOR
Intervention: ASP9226 (30 mg)
Number of subjects: 24
Study 29378016 — intervention group
Group type: COMPARATOR
Intervention: ASP9226 (50 mg)
Number of subjects: 24
Study 29378016 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 24
Study 27225949 — intervention group
Group type: EXPERIMENTAL
Intervention: Late follicular phase (day 14)
Number of subjects: 11
Study 27225949 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (COX inhibition)
Number of subjects: 11
Study 27225949 — intervention group
Group type: COMPARATOR
Intervention: Early follicular phase (day 3)
Number of subjects: 11
Study 24520664 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine + tadalafil
Number of subjects: 110
Study 24520664 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate + tadalafil
Number of subjects: 110
Study 24520664 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety of medication
Number of subjects: 110
Study 22847195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (1000 mg of vitamin C, 800 IU of vitamin E, and 300 mg of Coenzyme Q‐10) for 14 days
Number of subjects: 20
Study 22847195 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (HF) meal
Number of subjects: 20
Study 22847195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (LF) meal
Number of subjects: 20
Study 22847195 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study 20014878 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 0
Study 17589629 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine
Number of subjects: 62
Study 17589629 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine without epinephrine
Number of subjects: 62
Study 15805347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary-behavioral-physical activity intervention
Number of subjects: 46
Study 12151908 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ) 10 mg/day
Number of subjects: 60
Study 12151908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 2000 IU/day
Number of subjects: 60
Study 12151908 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Donepezil vs Vitamin E
Number of subjects: 60
Study 10539746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-MJ snack consumed 5 min before individual peak of hyperglycemia
Number of subjects: 11
Study 10539746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-MJ snack consumed 40 min after individual peak of hyperglycemia
Number of subjects: 11
Study 10539746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-MJ snack consumed 120 min before the time of dinner request
Number of subjects: 11
Study 8665881 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.036 mg kg‐1)
Number of subjects: 46
Study 8665881 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 46
Study 1669490 — intervention group
Group type: EXPERIMENTAL
Intervention: VitaStat
Number of subjects: 159
Study 1669490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap
Number of subjects: 159
Study 1669490 — intervention group
Group type: COMPARATOR
Intervention: Manual measurement
Number of subjects: 159
Study 7193006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorimetric method
Number of subjects: 0
Study 7193006 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC methods
Number of subjects: 0
Study 7193006 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological methods
Number of subjects: 0
Study 7193006 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of methods
Number of subjects: 0
Study 30586695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran (0.3 mg/kg via intravenous infusion once every 3 weeks for 18 months)
Number of subjects: 126
Study 30586695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 126
Study 30586695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28372660 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional turbulent free laminar airflow system
Number of subjects: 80
Study 28372660 — intervention group
Group type: COMPARATOR
Intervention: Absence of unidirectional turbulent free laminar airflow system
Number of subjects: 80
Study 28372660 — intervention group
Group type: COMPARATOR
Intervention: Longer duration of surgery
Number of subjects: 80
Study 28372660 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming system
Number of subjects: 80
Study 28372660 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric warming system
Number of subjects: 80
Study 28372660 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of health professionals in the OR
Number of subjects: 80
Study 26825829 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (PTX, 175 mg/m²) plus Carboplatin (CBDCA) (TC chemotherapy)
Number of subjects: 37
Study 26825829 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (DTX, 60 mg/m²) plus Carboplatin (CBDCA) (DC chemotherapy)
Number of subjects: 37
Study 26825829 — intervention group
Group type: COMPARATOR
Intervention: Both TC and DC chemotherapy
Number of subjects: 37
Study 25902653 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium (1 g/day intravenously for 2 weeks then orally until 1.5 months)
Number of subjects: 140
Study 25902653 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium
Number of subjects: 140
Study 22087585 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day free plant sterols and stanols
Number of subjects: 32
Study 22087585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18713481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 20
Study 17367312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks
Number of subjects: 100
Study 17367312 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks
Number of subjects: 100
Study 17367312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 100
Study 17367312 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 100
Study 17367312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Atorvastatin
Number of subjects: 100
Study 15539727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial Blake drain
Number of subjects: 202
Study 15539727 — intervention group
Group type: COMPARATOR
Intervention: Intrapericardial semirigid drain
Number of subjects: 202
Study 11449026 — intervention group
Group type: EXPERIMENTAL
Intervention: active rTMS
Number of subjects: 33
Study 11449026 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 33
Study 9684123 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum fluid intake (Group 1)
Number of subjects: 117
Study 9684123 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of mineral water per day (Group 2)
Number of subjects: 117
Study 7922450 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 0
Study 7922450 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study 7922450 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors in combination with specialized nutrition
Number of subjects: 0
Study 3149548 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (various doses, intra-arterial)
Number of subjects: 8
Study 3149548 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (1 to 20 micrograms, intra-arterial)
Number of subjects: 8
Study 31822477 — intervention group
Group type: EXPERIMENTAL
Intervention: iSPRINT NMT warm-up (15 min, including aerobic, agility, strength, and balance exercises)
Number of subjects: 1067
Study 31822477 — intervention group
Group type: EXPERIMENTAL
Intervention: iSPRINT NMT warm-up
Number of subjects: 1067
Study 31822477 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-practice warm-up
Number of subjects: 1067
Study 29359313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supraclavicular and PECS II block (Group PECS)
Number of subjects: 36
Study 29359313 — intervention group
Group type: COMPARATOR
Intervention: Combined supraclavicular and sham block (Group SCB)
Number of subjects: 36
Study 28455199 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Body Compression Garment (UBCG)
Number of subjects: 20
Study 28455199 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 26576946 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 335
Study 26576946 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Motivational Interviewing and Problem Solving Therapy (MI-PST)
Number of subjects: 335
Study 26576946 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational Control Group (CG)
Number of subjects: 335
Study 23990896 — intervention group
Group type: EXPERIMENTAL
Intervention: moodManager + TeleCoach
Number of subjects: 101
Study 23990896 — intervention group
Group type: COMPARATOR
Intervention: self-directed moodManager
Number of subjects: 101
Study 23990896 — intervention group
Group type: COMPARATOR
Intervention: waitlist control (WLC)
Number of subjects: 101
Study 21039351 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at target effect-site concentrations of 2.0, 2.5, 3.0, 3.5, and 4.0 microg/ml during TCI with sufentanil (0.2 ng/ml)
Number of subjects: 160
Study 21039351 — intervention group
Group type: COMPARATOR
Intervention: Propofol at target effect-site concentrations
Number of subjects: 160
Study 19925662 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux Disease Questionnaire (RDQ)
Number of subjects: 18000
Study 19925662 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rome II questionnaire
Number of subjects: 18000
Study 19925662 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 18000
Study 19925662 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-item Short Form Health Survey (SF-36)
Number of subjects: 18000
Study 19925662 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 18000
Study 17133564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 to 3 g/day with reduced CNI dose (≥50% of initial dose)
Number of subjects: 56
Study 17133564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMF, CNI dose not reduced below 75% of initial dose)
Number of subjects: 56
Study 12960821 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T/ddI
Number of subjects: 21
Study 12960821 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC
Number of subjects: 21
Study 12960821 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/ddI
Number of subjects: 21
Study 12960821 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from d4T/ddI to ZDV/3TC
Number of subjects: 21
Study 12960821 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from ZDV/3TC to d4T/ddI
Number of subjects: 21
Study 12960821 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from ZDV/3TC/ddI to d4T/3TC/abacavir
Number of subjects: 21
Study 11050639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric ammonium citrate (FAC)
Number of subjects: 203
Study 9350071 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitting immediately)
Number of subjects: 182
Study 9350071 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (control group)
Number of subjects: 182
Study 9350071 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful quitters (after 26 weeks)
Number of subjects: 182
Study 9350071 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful quitters (after 26 weeks)
Number of subjects: 182
Study 1279468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg 4 times a day e.v.)
Number of subjects: 40
Study 1279468 — intervention group
Group type: COMPARATOR
Intervention: No anti H2 treatment (Control)
Number of subjects: 40
Study 1279468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 40
Study 3769898 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg meptazinol i.m.
Number of subjects: 24
Study 3769898 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine i.m.
Number of subjects: 24
Study 3769898 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 24
Study 28699054 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT)
Number of subjects: 36
Study 28699054 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive behavioral therapy (CBT)
Number of subjects: 36
Study 26482543 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (6 mg) in tomato juice
Number of subjects: 20
Study 26482543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tomato juice)
Number of subjects: 20
Study 26482543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Doxepin and Placebo
Number of subjects: 20
Study 24728774 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening (pulse and ECG)
Number of subjects: 200
Study 24728774 — intervention group
Group type: COMPARATOR
Intervention: Systematic screening (postal invitation for ECG)
Number of subjects: 200
Study 22200728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan, 125 mg two times per day, n = 28
Number of subjects: 46
Study 22200728 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 28
Number of subjects: 46
Study 20659956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 20659956 — intervention group
Group type: COMPARATOR
Intervention: Interferon β‐1a
Number of subjects: 0
Study 20659956 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from post‐alemtuzumab peripheral blood mononuclear cell cultures
Number of subjects: 0
Study 18568482 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (administered orally twice daily until disease progression or intolerance)
Number of subjects: 52
Study 15752950 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d of oral folic acid for 4 weeks
Number of subjects: 26
Study 15752950 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 26
Study 12030913 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (mean intake 84%)
Number of subjects: 57
Study 12030913 — intervention group
Group type: COMPARATOR
Intervention: Formula milk (less than 25% breast milk, mean intake 3.3%)
Number of subjects: 57
Study 12030913 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 57
Study 12030913 — intervention group
Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 57
Study 10342484 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage sessions of 10 minutes per day in combination with treatment with pressure garments
Number of subjects: 30
Study 10342484 — intervention group
Group type: COMPARATOR
Intervention: Pressure garments alone
Number of subjects: 30
Study 8595539 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays/nostril bid
Number of subjects: 264
Study 8595539 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays/nostril qd
Number of subjects: 264
Study 8595539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlorpheniramine maleate, 12 mg bid
Number of subjects: 264
Study 8595539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 1790542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg twice daily)
Number of subjects: 30
Study 1790542 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (60 mg thrice daily)
Number of subjects: 30
Study 6111632 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60‐120 mg/day)
Number of subjects: 40
Study 6111632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30049524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane OLV
Number of subjects: 24
Study 30049524 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane OLV
Number of subjects: 24
Study 30049524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OLV groups
Number of subjects: 24
Study 28453849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with initial efavirenz
Number of subjects: 1016
Study 28453849 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1016
Study 25784719 — intervention group
Group type: COMPARATOR
Intervention: CDP7657 IV (0.004-5 mg/kg)
Number of subjects: 45
Study 25784719 — intervention group
Group type: COMPARATOR
Intervention: CDP7657 IV (5-60 mg/kg)
Number of subjects: 45
Study 25784719 — intervention group
Group type: COMPARATOR
Intervention: CDP7657
Number of subjects: 45